UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study ...

Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, ...

The clinical trial with MT1988 will be co-led by Dr. Scott Woods and Dr. Youngsun Cho from Yale School of Medicine, Dr. Carrie Bearden from University of California, Los Angeles (UCLA), Dr. John ...

Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to address the cognitive symptoms that have long remained untreated.

MANCHESTER, England, Nov. 26, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in ...

The AIM-traded firm said the clinical study would evaluate MT1988, a novel therapy targeting cognitive impairment associated with schizophrenia, in a proof-of-principle trial under the ...

Dr. Kiri Granger, Chief Scientific Officer of Monument Therapeutics, commented: "This trial marks an exciting milestone for Monument to evaluate MT1988 in a patient population with our proprietary ...